Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and methods for treating cancer

A chimeric antigen receptor, cell technology, applied in chemical instruments and methods, used to target specific cell fusion, drug combination, etc., can solve problems such as undetectable

Pending Publication Date: 2019-12-03
UNIV OF SOUTHERN CALIFORNIA
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In contrast, PD-L1 expression was undetectable in normal tissues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating cancer
  • Compositions and methods for treating cancer
  • Compositions and methods for treating cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0113] experimental method

[0114] mice. Six to eight week old female NOD.Cg-Prkdc scid IL2Rg tm1Wj1 .Sz(NSG) mice were purchased from Jackson Laboratories (Farmington, CT). All animal studies were conducted in accordance with the NIH's Animal Care and Use Committee guidelines and were performed under protocols approved by the NCI's Animal Care and Use Committee.

[0115]Cell culture and antibodies. Cell lines SKOV3 and 293T were obtained from ATCC. Lung cancer line NCI-H292 was kindly provided by Dr. Ite Laird-Offringa (University of Southern California, Los Angeles, CA). The H292-CD19 and SKOV3-CD19 cell lines were generated by transducing parental NCI-H292 and SKOV3 cells with a lentiviral vector encoding the cDNA of human CD19. Transduced H292 and SKOV3 cells were stained with an anti-human CD19 antibody (BioLegend, San Diego, CA) and sorted to generate a relatively pure population of CD19 overexpressing cells. SKOV3, SKOV3-CD19, NCI-H292 and H292-CD19 cells were m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described herein are compositions a genetically modified comprising nucleic acids encoding a chimeric antigen receptor (CAR) and a checkpoint inhibitor and methods for using the compositions to treatcancer.

Description

[0001] Cross References to Related Applications [0002] This application includes claiming priority under 35 U.S.C § 119(e) to U.S. Provisional Application No. 62 / 487,358, filed April 19, 2017, which is hereby incorporated by reference in its entirety. [0003] Statement Regarding Federally Sponsored Research or Development [0004] This invention was made with government support under Grant No. AI068978 and No. EB017206 awarded by the National Institutes of Health. The US Government has certain rights in this invention. technical field [0005] Described herein are compositions comprising T cells comprising a chimeric antigen receptor (CAR) and a checkpoint inhibitor (CPI), and methods of using the compositions to treat cancer. Background technique [0006] All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The follow...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61P35/00C07K14/705C07K14/725C07K16/28C07K16/30
CPCA61P35/00A61K39/39541C07K16/2803C07K16/2818A61K2039/505A61K2039/507C07K2317/31C07K2317/622C07K2319/03C07K2319/33C07K14/7051A61K2239/59A61K39/4611A61K2239/55A61K2239/38A61K2239/31A61K39/464412A61K39/4631A61K2300/00A61K35/17A61K38/1774A61K39/3955A61K45/06A61K2039/5154A61K2039/5158A61K2039/545C07K14/70517C07K14/70521C07K2317/73C07K2317/76C07K2319/30
Inventor 王品纳特纳雷·西里翁李思
Owner UNIV OF SOUTHERN CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com